Sarcoidosis in America Analysis Based on Health Care Use

被引:272
作者
Baughman, Robert P. [1 ]
Field, Shelli [2 ]
Costabel, Ulrich [3 ]
Crystal, Ronald G. [4 ]
Culver, Daniel A. [5 ]
Drent, Marjolein [6 ]
Judson, Marc A. [7 ]
Wolff, Gerhard [8 ]
机构
[1] Univ Cincinnati, Med Ctr, Dept Internal Med, 1001 Holmes Bldg,Eden Ave, Cincinnati, OH 45267 USA
[2] Optum, Philadelphia, PA USA
[3] Univ Duisburg Essen, Ruhrlandklin, Essen, Germany
[4] Cornell Univ, Weill Cornell Med Coll, New York, NY 10021 USA
[5] Cleveland Clin Fdn, Cleveland, OH USA
[6] Maastricht Univ, Fac Hlth Med & Life Sci, Dept Pharmacol & Toxicol, Maastricht, Netherlands
[7] Albany Med Coll, Albany, NY 12208 USA
[8] Mitsubishi Tanabe Pharma Dev Amer, Jersey City, NJ USA
关键词
sarcoidosis; health care use; epidemiology; race; sex; PULMONARY-HYPERTENSION; UNITED-STATES; CLINICAL CHARACTERISTICS; THERAPY; EPIDEMIOLOGY; RECOMMENDATIONS; PREDICTORS; EXPERIENCE; PROGNOSIS; MORTALITY;
D O I
10.1513/AnnalsATS.201511-760OC
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Rationale: There have been no recent comprehensive studies of the epidemiology of sarcoidosis in the United States. Changes in health care use have made available access to data on large numbers of patients with sarcoidosis. Objectives: To use a U.S. national health care database to gather data on patients with sarcoidosis identified over a 3-year period who were 18 years of age and older, and to determine health care costs for these patients. Methods: The Optum health care database was queried for a 3-year period (2010-2013). This database includes approximately 15% of U.S. residents. The incidence rate of sarcoidosis was calculated for new cases identified in each year. Calculation of prevalence was based on any patient with sarcoidosis seen during the year. Incidence and prevalence rates are reported per 100,000 patients. Measurements and Main Results: A total of 29,372 adult patients with sarcoidosis were identified. Of these, 14,700 (55%) were over 55 years of age at the time of diagnosis. The incidence and prevalence rates were higher for African Americans (17.8 and 141.4 per 100,000, respectively) than for white individuals (8.1 and 49.8), Hispanics (4.3 and 21.7), or Asians (3.2 and 18.9). Women were two times more likely to have sarcoidosis, with the highest prevalence for sarcoidosis noted in African American women (178.5). Overall, the yearly health care cost reported for patients with sarcoidosis was low, with a median of $18,663 per year. However, the yearly cost for the top 5% was $93,201. Conclusions: For patients 18 years of age and older enrolled in a U.S. national administrative database, sarcoidosis was more common among African Americans, but it was reported for all four of the major ethnic groups studied. While health care costs were relatively small for most patients, the cost of care for some patients was considerable.
引用
收藏
页码:1244 / 1252
页数:9
相关论文
共 44 条
[1]   Treatment of Sarcoidosis-Associated Pulmonary Hypertension A Two-Center Experience [J].
Barnett, Christopher F. ;
Bonura, Eric J. ;
Nathan, Steven D. ;
Ahmad, Shahzad ;
Shlobin, Oksana A. ;
Osei, Kwabena ;
Zaiman, Ari L. ;
Hassoun, Paul M. ;
Moller, David R. ;
Barnett, Scott D. ;
Girgis, Reda E. .
CHEST, 2009, 135 (06) :1455-1461
[2]   Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement [J].
Baughman, Robert P. ;
Drent, Marjolein ;
Kavuru, Mani ;
Judson, Marc A. ;
Costabel, Ulrich ;
du Bois, Roland ;
Albera, Carlo ;
Brutsche, Martin ;
Davis, Gerald ;
Donohue, James F. ;
Mueller-Quernheim, Joachim ;
Schlenker-Herceg, Rozsa ;
Flavin, Susan ;
Lo, Kim Hung ;
Oemar, Barry ;
Barnathan, Elliot S. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 174 (07) :795-802
[3]   Bosentan for Sarcoidosis-Associated Pulmonary Hypertension A Double-Blind Placebo Controlled Randomized Trial [J].
Baughman, Robert P. ;
Culver, Daniel A. ;
Cordova, Francis C. ;
Padilla, Maria ;
Gibson, Kevin F. ;
Lower, Elyse E. ;
Engel, Peter J. .
CHEST, 2014, 145 (04) :810-817
[4]   Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients [J].
Baughman, Robert P. ;
Lower, Elyse E. .
RESPIRATORY MEDICINE, 2013, 107 (12) :2009-2013
[5]   Established and experimental medical therapy of pulmonary sarcoidosis [J].
Baughman, Robert P. ;
Nunes, Hilario ;
Sweiss, Nadera J. ;
Lower, Elyse E. .
EUROPEAN RESPIRATORY JOURNAL, 2013, 41 (06) :1424-1438
[6]  
Baughman RP, 2012, EXPERT REV CLIN IMMU, V8, P95, DOI [10.1586/ECI.11.84, 10.1586/eci.11.84]
[7]   Survival in Sarcoidosis-Associated Pulmonary Hypertension The Importance of Hemodynamic Evaluation [J].
Baughman, Robert P. ;
Engel, Peter J. ;
Taylor, Lisa ;
Lower, Elyse E. .
CHEST, 2010, 138 (05) :1078-1085
[8]   Clinical characteristics of patients in a case control study of sarcoidosis [J].
Baughman, RP ;
Teirstein, AS ;
Judson, MA ;
Rossman, MD ;
Yeager, H ;
Bresnitz, EA ;
DePalo, L ;
Hunninghake, G ;
Iannuzzi, MC ;
Johns, CJ ;
McLennan, G ;
Moller, DR ;
Newman, LS ;
Rabin, DL ;
Rose, C ;
Rybicki, B ;
Weinberger, SE ;
Terrin, ML ;
Knatterud, GL ;
Cherniak, R .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (10) :1885-1889
[9]   Presenting characteristics as predictors of duration of treatment in sarcoidosis [J].
Baughman, RP ;
Judson, MA ;
Teirstein, A ;
Yeager, H ;
Rossman, M ;
Knatterud, GL ;
Thompson, B .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2006, 99 (05) :307-315
[10]  
Baughman RP, 1997, SARCOIDOSIS VASC DIF, V14, P154